AI and Autonomy AI helps NHS cut lung cancer scan review times in half The government said AI-powered X-ray tools are already available in roughly half of NHS trusts across England Joseph Morton3 days ago
AI and Autonomy Ainos deploys ‘AI Nose’ tech for environmental monitoring in Taiwan ER These devices have already proven their worth for environmental monitoring in advanced manufacturing Rowan Dunne3 days ago
Medical and Pharmaceutical Micro-X and University of Sydney undertake mini lung CT scanner research They have secured AUD$1.9 million for their project Rowan Dunne4 days ago
AI and Autonomy Five technologies moving from science fiction to reality: A Mugglehead roundup The goal is to solve longstanding problems that have resisted traditional approaches Joseph MortonJune 12, 2026
Medical and Pharmaceutical Liquid chromatography-mass spectrometry proves its worth in lung cancer screening It is highly impactful for blood draws and breath samples Rowan DunneJune 12, 2026
Medical and Pharmaceutical BioMark expands lung cancer screening portfolio with patented urine test It is one of a select few pursuing this variety of diagnostics Rowan DunneJune 10, 2026
Medical and Pharmaceutical AI-powered blood test promises lung cancer detection 5 years in advance British scientists used the biopsy to detect a 14-protein blood signature linked to the disease Rowan DunneJune 4, 2026
Medical and Pharmaceutical International research surge highlights asbestos health crisis It's being overlooked in lung cancer screening, causing a record number of legal claims and may be deadlier than once thought Rowan DunneJune 2, 2026
Medical and Pharmaceutical Cambridge researchers develop urine test that could detect lung cancer years earlier Scientists said the test may also monitor whether treatment works and detect signs of relapse before patients experience symptoms Joseph MortonMay 28, 2026
Medical and Pharmaceutical China’s Westlake University develops palm-sized lung cancer blood test It could surpass current liquid biopsy options after further evaluation Rowan DunneMay 27, 2026